Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide
Go back to Eli Lilly shares phase 3 data on triple agonist weight loss drug retatrutide| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1215.02 -16.92 (1.37%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1231.94 | 52 Week High | $88.16 | |||
| Open | $1230.65 | 52 Week Low | $67.88 | |||
| Day High | $1238.00 | P/E | 281.25 | |||
| Day Low | $1209.53 | EPS | $4.32 | |||
| Volume | 2,110,641 | |||||
